Increased Erythropoiesis in Mice Injected with Submicrogram Quantities of Pseudouridine-containing MRNA Encoding Erythropoietin

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2012 Feb 16

PMID 22334017

Citations 152

Authors

Katalin Kariko

Hiromi Muramatsu

Jason M Keller

Drew Weissman

Affiliations

Soon will be listed here.

Abstract

Advances in the optimization of in vitro-transcribed mRNA are bringing mRNA-mediated therapy closer to reality. In cultured cells, we recently achieved high levels of translation with high-performance liquid chromatography (HPLC)-purified, in vitro-transcribed mRNAs containing the modified nucleoside pseudouridine. Importantly, pseudouridine rendered the mRNA non-immunogenic. Here, using erythropoietin (EPO)-encoding mRNA complexed with TransIT-mRNA, we evaluated this new generation of mRNA in vivo. A single injection of 100 ng (0.005 mg/kg) mRNA elevated serum EPO levels in mice significantly by 6 hours and levels were maintained for 4 days. In comparison, mRNA containing uridine produced 10-100-fold lower levels of EPO lasting only 1 day. EPO translated from pseudouridine-mRNA was functional and caused a significant increase of both reticulocyte counts and hematocrits. As little as 10 ng mRNA doubled reticulocyte numbers. Weekly injection of 100 ng of EPO mRNA was sufficient to increase the hematocrit from 43 to 57%, which was maintained with continued treatment. Even when a large amount of pseudouridine-mRNA was injected, no inflammatory cytokines were detectable in plasma. Using macaques, we could also detect significantly-increased serum EPO levels following intraperitoneal injection of rhesus EPO mRNA. These results demonstrate that HPLC-purified, pseudouridine-containing mRNAs encoding therapeutic proteins have great potential for clinical applications.

Citing Articles

Advancements in pseudouridine modifying enzyme and cancer.

Liu K, Zhang S, Liu Y, Hu X, Gu X Front Cell Dev Biol. 2024; 12:1465546.

PMID: 39737343 PMC: 11683142. DOI: 10.3389/fcell.2024.1465546.

Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy.

Laila U, An W, Xu Z Front Immunol. 2024; 15:1448489.

PMID: 39654897 PMC: 11625737. DOI: 10.3389/fimmu.2024.1448489.

Fabrication of mRNA encapsulated lipid nanoparticles using state of the art SMART-MaGIC technology and transfection in vitro.

Heshmati N, Chakka L, Zhang Y, Maniruzzaman M Sci Rep. 2024; 14(1):22714.

PMID: 39349578 PMC: 11442764. DOI: 10.1038/s41598-024-73804-y.

Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation.

Chen H, Liu D, Aditham A, Guo J, Huang J, Kostas F Nat Biotechnol. 2024; .

PMID: 39313647 DOI: 10.1038/s41587-024-02393-y.

Current landscape of mRNA technologies and delivery systems for new modality therapeutics.

Lu R, Hsu H, Perez S, Kumari M, Chen G, Hong M J Biomed Sci. 2024; 31(1):89.

PMID: 39256822 PMC: 11389359. DOI: 10.1186/s12929-024-01080-z.

References

Ngumbela K, Ryan K, Sivamurthy R, Brockman M, Gandhi R, Bhardwaj N . Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells. PLoS One. 2008; 3(6):e2356. PMC: 2387063. DOI: 10.1371/journal.pone.0002356. View

Nallagatla S, Bevilacqua P . Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA. 2008; 14(6):1201-13. PMC: 2390794. DOI: 10.1261/rna.1007408. View

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

Kormann M, Hasenpusch G, Aneja M, Nica G, Flemmer A, Herber-Jonat S . Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. 2011; 29(2):154-7. DOI: 10.1038/nbt.1733. View

Kariko K, Muramatsu H, Ludwig J, Weissman D . Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011; 39(21):e142. PMC: 3241667. DOI: 10.1093/nar/gkr695. View

Kharagjitsingh A, Korevaar J, Vandenbroucke J, Boeschoten E, Krediet R, Daha M . Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int. 2005; 68(3):1215-22. DOI: 10.1111/j.1523-1755.2005.00514.x. View

Anderson B, Muramatsu H, Jha B, Silverman R, Weissman D, Kariko K . Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 2011; 39(21):9329-38. PMC: 3241635. DOI: 10.1093/nar/gkr586. View

Anderson B, Muramatsu H, Nallagatla S, Bevilacqua P, Sansing L, Weissman D . Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010; 38(17):5884-92. PMC: 2943593. DOI: 10.1093/nar/gkq347. View

Weissman D, Ni H, Scales D, Dude A, Capodici J, McGibney K . HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol. 2000; 165(8):4710-7. DOI: 10.4049/jimmunol.165.8.4710. View

10.

Kramer M, Schulte B, Eleveld-Trancikova D, van Hout-Kuijer M, Toonen L, Tel J . Cross-talk between human dendritic cell subsets influences expression of RNA sensors and inhibits picornavirus infection. J Innate Immun. 2010; 2(4):360-70. DOI: 10.1159/000300568. View

11.

Bennett C, Cournoyer D, Carson K, Rossert J, Luminari S, Evens A . Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005; 106(10):3343-7. PMC: 1895064. DOI: 10.1182/blood-2005-02-0508. View

12.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

13.

Chenuaud P, Larcher T, Rabinowitz J, Provost N, Cherel Y, Casadevall N . Autoimmune anemia in macaques following erythropoietin gene therapy. Blood. 2004; 103(9):3303-4. DOI: 10.1182/blood-2003-11-3845. View

14.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

15.

Zhong F, Cao W, Chan E, Tay P, Cahya F, Zhang H . Deviation from major codons in the Toll-like receptor genes is associated with low Toll-like receptor expression. Immunology. 2004; 114(1):83-93. PMC: 1782050. DOI: 10.1111/j.1365-2567.2004.02007.x. View

16.

Weide B, Carralot J, Reese A, Scheel B, Eigentler T, Hoerr I . Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008; 31(2):180-8. DOI: 10.1097/CJI.0b013e31815ce501. View

17.

Nallagatla S, Hwang J, Toroney R, Zheng X, Cameron C, Bevilacqua P . 5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science. 2007; 318(5855):1455-8. DOI: 10.1126/science.1147347. View

18.

Lee D, Son W, Ha B, Oh M, Yoo O . The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem Biophys Res Commun. 2005; 339(1):380-5. DOI: 10.1016/j.bbrc.2005.11.034. View

19.

Raper S, Chirmule N, Lee F, Wivel N, Bagg A, Gao G . Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003; 80(1-2):148-58. DOI: 10.1016/j.ymgme.2003.08.016. View

20.

Kariko K, Ni H, Capodici J, Lamphier M, Weissman D . mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004; 279(13):12542-50. DOI: 10.1074/jbc.M310175200. View